Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2

Journal of Immunology

Volumn 190, Issue 11, 2013, Pages 5894-5902

  Qian, Xuesong ^a   Gu, Ling ^a   Ning, Huan ^a   Zhang, Yanping ^a   Hsueh, Eddy C ^a   Fu, Mingui ^b   Hu, Xiaoyu ^c   Wei, Lin ^a,d   Hoft, Daniel F ^a   Liu, Jianguo ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

^d HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FORSKOLIN; INTERLEUKIN 23; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROTEIN P19;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOCKING FACTOR; BLOOD; BREAST EPITHELIUM; CANCER PATIENT; CANCER TISSUE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SPLEEN; TH17 CELL; TUMOR MICROENVIRONMENT;

ANIMALS; BREAST NEOPLASMS; CELL LINE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIN-DEPENDENT KINASE INHIBITOR P19; DINOPROSTONE; FEMALE; GENE EXPRESSION; INTERLEUKIN-23; MICE; NEOPLASMS; PROMOTER REGIONS, GENETIC; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TH17 CELLS; TRANSCRIPTION, GENETIC; TUMOR MICROENVIRONMENT;

EID: 84878047707     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203141     Document Type: Article

References (40)

1. DeNardo, D. G., and L. M. Coussens. 2007. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9: 212.
2. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867. (Pubitemid 36019639)
3. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539-545. (Pubitemid 32173595)
4. Korn, T., E. Bettelli, M. Oukka, and V. K. Kuchroo. 2009. IL-17 and Th17 cells. Annu. Rev. Immunol. 27: 485-517.
5. Zou, W., and N. P. Restifo. 2010. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10: 248-256.
6. Murugaiyan, G., and B. Saha. 2009. Protumor vs antitumor functions of IL-17. J. Immunol. 183: 4169-4175.
7. Su, X., J. Ye, E. C. Hsueh, Y. Zhang, D. F. Hoft, and G. Peng. 2010. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 184: 1630-1641.
8. Derhovanessian, E., V. Adams, K. Hähnel, A. Groeger, H. Pandha, S. Ward, and G. Pawelec. 2009. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int. J. Cancer 125: 1372-1379.
9. Zhang, B., G. Rong, H. Wei, M. Zhang, J. Bi, L. Ma, X. Xue, G.Wei, X. Liu, and G. Fang. 2008. The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 374: 533-537.
10. Yang, L., D. E. Anderson, C. Baecher-Allan, W. D. Hastings, E. Bettelli, M. Oukka, V. K. Kuchroo, and D. A. Hafler. 2008. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 454: 350-352.
11. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189. (Pubitemid 43214587)
12. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
13. Mangan, P. R., L. E. Harrington, D. B. O'Quinn, W. S. Helms, D. C. Bullard, C. O. Elson, R. D. Hatton, S. M. Wahl, T. R. Schoeb, and C. T. Weaver. 2006. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-234.
14. Korn, T., E. Bettelli, W. Gao, A. Awasthi, A. Jäger, T. B. Strom, M. Oukka, and V. K. Kuchroo. 2007. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448: 484-487. (Pubitemid 47123515)
15. Wilson, N. J., K. Boniface, J. R. Chan, B. S. McKenzie, W. M. Blumenschein, J. D. Mattson, B. Basham, K. Smith, T. Chen, F. Morel, et al. 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8: 950-957. (Pubitemid 47300009)
16. Volpe, E., N. Servant, R. Zollinger, S. I. Bogiatzi, P. Hupé, E. Barillot, and V. Soumelis. 2008. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T (H)-17 responses. Nat. Immunol. 9: 650-657. (Pubitemid 351712635)
17. Langowski, J. L., X. Zhang, L. Wu, J. D. Mattson, T. Chen, K. Smith, B. Basham, T. McClanahan, R. A. Kastelein, and M. Oft. 2006. IL-23 promotes tumour incidence and growth. Nature 442: 461-465. (Pubitemid 44264796)
18. Teng, M. W., D. M. Andrews, N. McLaughlin, B. von Scheidt, S. F. Ngiow, A. Möller, G. R. Hill, Y. Iwakura, M. Oft, and M. J. Smyth. 2010. IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc. Natl. Acad. Sci. USA 107: 8328-8333.
19. Wang, Y. Q., S. Ugai, O. Shimozato, L. Yu, K. Kawamura, H. Yamamoto, T. Yamaguchi, H. Saisho, and M. Tagawa. 2003. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int. J. Cancer 105: 820-824. (Pubitemid 36706106)
20. Lo, C. H., S. C. Lee, P. Y. Wu, W. Y. Pan, J. Su, C. W. Cheng, S. R. Roffler, B. L. Chiang, C. N. Lee, C. W. Wu, and M. H. Tao. 2003. Antitumor and antimetastatic activity of IL-23. J. Immunol. 171: 600-607. (Pubitemid 36871367)
21. Oppmann, B., R. Lesley, B. Blom, J. C. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
22. Carmody, R. J., Q. Ruan, H. C. Liou, and Y. H. Chen. 2007. Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. J. Immunol. 178: 186-191. (Pubitemid 46033600)
23. Mise-Omata, S., E. Kuroda, J. Niikura, U. Yamashita, Y. Obata, and T. S. Doi. 2007. A proximal kappaB site in the IL-23 p19 promoter is responsible for RelA-and c-Rel-dependent transcription. J. Immunol. 179: 6596-6603.
24. Liu, W., X. Ouyang, J. Yang, J. Liu, Q. Li, Y. Gu, M. Fukata, T. Lin, J. C. He, M. Abreu, et al. 2009. AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J. Biol. Chem. 284: 24006-24016.
25. Al-Salleeh, F., and T. M. Petro. 2008. Promoter analysis reveals critical roles for SMAD-3 and ATF-2 in expression of IL-23 p19 in macrophages. J. Immunol. 181: 4523-4533.
26. Ruhnke, M., H. Ungefroren, A. Nussler, F. Martin, M. Brulport, W. Schormann, J. G. Hengstler, W. Klapper, K. Ulrichs, J. A. Hutchinson, et al. 2005. Differentiation of in vitro-modified human peripheral blood monocytes into hepatocyte- like and pancreatic islet-like cells. Gastroenterology 128: 1774-1786. (Pubitemid 40824688)
27. Qian, X., H. Ning, J. Zhang, D. F. Hoft, D. J. Stumpo, P. J. Blackshear, and J. Liu. 2011. Posttranscriptional regulation of IL-23 expression by IFN-gamma through tristetraprolin. J. Immunol. 186: 6454-6464.
28. Pulaski, B. A., and S. Ostrand-Rosenberg. 1998. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493. (Pubitemid 28193612)
29. Mi, Z., H. Guo, P. Y. Wai, C. Gao, J. Wei, and P. C. Kuo. 2004. Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. J. Biol. Chem. 279: 46659-46667. (Pubitemid 39518312)
30. Morecki, S., L. Yacovlev, and S. Slavin. 1998. Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma. Int. J. Cancer 75: 894-899. (Pubitemid 28134115)
31. Rakhmilevich, A. L., K. Janssen, Z. Hao, P. M. Sondel, and N. S. Yang. 2000. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther. 7: 826-838. (Pubitemid 30437282)
32. Shi, X., S. Cao, M. Mitsuhashi, Z. Xiang, and X. Ma. 2004. Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms. J. Immunol. 172: 4111-4122. (Pubitemid 38375223)
33. Qian, X., J. Zhang, and J. Liu. 2011. Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway. J. Biol. Chem. 286: 2111-2120.
34. Hollmann, C. A., F. S. Kittrell, D. Medina, and J. S. Butel. 2001. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis. Oncogene 20: 7645-7657. (Pubitemid 33111864)
35. Zhang, J., X. Qian, H. Ning, J. Yang, H. Xiong, and J. Liu. 2010. Activation of IL-27 p28 gene transcription by interferon regulatory factor 8 in cooperation with interferon regulatory factor 1. J. Biol. Chem. 285: 21269-21281.
36. Mitsuhashi, M., J. Liu, S. Cao, X. Shi, and X. Ma. 2004. Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J. Leukoc. Biol. 76: 322-332. (Pubitemid 39006945)
37. Korn, T., E. Bettelli, M. Oukka, and V. K. Kuchroo. 2009. IL-17 and Th17 cells. Annu. Rev. Immunol. 27: 485-517.
38. Khayrullina, T., J. H. Yen, H. Jing, and D. Ganea. 2008. In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J. Immunol. 181: 721-735.
39. Boniface, K., K. S. Bak-Jensen, Y. Li, W. M. Blumenschein, M. J. McGeachy, T. K. McClanahan, B. S. McKenzie, R. A. Kastelein, D. J. Cua, and R. de Waal Malefyt. 2009. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 206: 535- 548.
40. Yao, C., D. Sakata, Y. Esaki, Y. Li, T. Matsuoka, K. Kuroiwa, Y. Sugimoto, and S. Narumiya. 2009. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 15: 633-640.